MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

Compare

625 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MLTX Analyst Ratings

Moderate Buy

9 Buy

2 Hold

1 Sell

Based on 12 analysts giving stock ratings to

MoonLake

Immunotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MLTX Stock 12 Month Forecast

Average Price Target

$24.10

▲(40.94% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for MoonLake Immunotherapeutics in the last 3 months. The average price target is $24.10 with a high forecast of $45.00 and a low forecast of $5.00. The average price target represents a 40.94% change from the last price of $17.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","59":"$59","17.75":"$17.75","31.5":"$31.5","45.25":"$45.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,17.75,31.5,45.25,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.18,15.627692307692307,18.075384615384614,20.52307692307692,22.97076923076923,25.418461538461536,27.866153846153846,30.313846153846153,32.761538461538464,35.20923076923077,37.65692307692308,40.104615384615386,42.55230769230769,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.18,14.02,14.86,15.7,16.54,17.38,18.22,19.060000000000002,19.9,20.740000000000002,21.58,22.42,23.26,{"y":24.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.18,12.55076923076923,11.92153846153846,11.292307692307691,10.663076923076922,10.033846153846152,9.404615384615385,8.775384615384615,8.146153846153846,7.516923076923076,6.887692307692307,6.258461538461538,5.629230769230769,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$45.00

Average Price Target$24.10

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

$32

Buy

87.13%

Upside

Reiterated

01/09/26

MoonLake price target raised to $32 from $26 at H.C. WainwrightMoonLake price target raised to $32 from $26 at H.C. Wainwright

Julian Harrison

BTIG

$24

Buy

40.35%

Upside

Upgraded

01/09/26

MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIGMoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG

Rami Katkhuda

LifeSci Capital

$16→$33

Buy

92.98%

Upside

Reiterated

01/08/26

MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating

Serge Belanger

Needham

$20

Buy

16.96%

Upside

Reiterated

01/08/26

MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating

Phil Nadeau

TD Cowen

Buy

―

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (NASDAQ: MLTX) and Ionis Pharmaceuticals (NASDAQ: IONS)

Kaveri Pohlman

Clear Street

$12→$45

Buy

163.16%

Upside

Reiterated

01/08/26

MoonLake Immunotherapeutics price target raised to $45 from $12 at Clear StreetMoonLake Immunotherapeutics price target raised to $45 from $12 at Clear Street

Yun Zhong

Wedbush

$18→$34

Buy

98.83%

Upside

Reiterated

01/08/26

De-Risked HS Pathway and Expanding PsA Optionality Underpin Buy Rating on MoonLake and Top-Idea Status for 2026

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Reiterated

12/04/25

FDA moving to one trial for approval could be positve for MoonLake, says CantorFDA moving to one trial for approval could be positve for MoonLake, says Cantor

Richard Law CFA

Goldman Sachs

$7→$8

Hold

-53.22%

Downside

Reiterated

11/07/25

MoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman SachsMoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman Sachs

Andreas Argyrides

Oppenheimer

$25→$30

Buy

75.44%

Upside

Reiterated

11/06/25

MoonLake Immunotherapeutics (MLTX) Receives a Buy from Oppenheimer

Brian Abrahams

RBC Capital

$10

Hold

-41.52%

Downside

Reiterated

11/05/25

RBC Capital Sticks to Its Hold Rating for MoonLake Immunotherapeutics (MLTX)

Samantha Semenkow

Citi

Sell

-70.76%

Downside

Downgraded

10/29/25

MoonLake Immunotherapeutics downgraded to Sell from Neutral at CitiMoonLake Immunotherapeutics downgraded to Sell from Neutral at Citi

Thomas Smith

Leerink Partners

$73→$14

Buy

-18.13%

Downside

Reiterated

10/01/25

MoonLake Immunotherapeutics (MLTX) Receives a Buy from Leerink Partners

Clara Dong

Jefferies

Hold

-53.22%

Downside

Downgraded

09/30/25

MoonLake Immunotherapeutics (MLTX) was downgraded to a Hold Rating at Jefferies

Yatin Suneja

Guggenheim

$80→$20

Buy

16.96%

Upside

Reiterated

09/29/25

Guggenheim cuts MoonLake Immunotherapeutics price target, removes as Best IdeaGuggenheim cuts MoonLake Immunotherapeutics price target, removes as Best Idea

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

$32

Buy

87.13%

Upside

Reiterated

01/09/26

MoonLake price target raised to $32 from $26 at H.C. WainwrightMoonLake price target raised to $32 from $26 at H.C. Wainwright

Julian Harrison

BTIG

$24

Buy

40.35%

Upside

Upgraded

01/09/26

MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIGMoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG

Rami Katkhuda

LifeSci Capital

$16→$33

Buy

92.98%

Upside

Reiterated

01/08/26

MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating

Serge Belanger

Needham

$20

Buy

16.96%

Upside

Reiterated

01/08/26

MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating

Phil Nadeau

TD Cowen

Buy

―

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (NASDAQ: MLTX) and Ionis Pharmaceuticals (NASDAQ: IONS)

Kaveri Pohlman

Clear Street

$12→$45

Buy

163.16%

Upside

Reiterated

01/08/26

MoonLake Immunotherapeutics price target raised to $45 from $12 at Clear StreetMoonLake Immunotherapeutics price target raised to $45 from $12 at Clear Street

Yun Zhong

Wedbush

$18→$34

Buy

98.83%

Upside

Reiterated

01/08/26

De-Risked HS Pathway and Expanding PsA Optionality Underpin Buy Rating on MoonLake and Top-Idea Status for 2026

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Reiterated

12/04/25

FDA moving to one trial for approval could be positve for MoonLake, says CantorFDA moving to one trial for approval could be positve for MoonLake, says Cantor

Richard Law CFA

Goldman Sachs

$7→$8

Hold

-53.22%

Downside

Reiterated

11/07/25

MoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman SachsMoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman Sachs

Andreas Argyrides

Oppenheimer

$25→$30

Buy

75.44%

Upside

Reiterated

11/06/25

MoonLake Immunotherapeutics (MLTX) Receives a Buy from Oppenheimer

Brian Abrahams

RBC Capital

$10

Hold

-41.52%

Downside

Reiterated

11/05/25

RBC Capital Sticks to Its Hold Rating for MoonLake Immunotherapeutics (MLTX)

Samantha Semenkow

Citi

Sell

-70.76%

Downside

Downgraded

10/29/25

MoonLake Immunotherapeutics downgraded to Sell from Neutral at CitiMoonLake Immunotherapeutics downgraded to Sell from Neutral at Citi

Thomas Smith

Leerink Partners

$73→$14

Buy

-18.13%

Downside

Reiterated

10/01/25

MoonLake Immunotherapeutics (MLTX) Receives a Buy from Leerink Partners

Clara Dong

Jefferies

Hold

-53.22%

Downside

Downgraded

09/30/25

MoonLake Immunotherapeutics (MLTX) was downgraded to a Hold Rating at Jefferies

Yatin Suneja

Guggenheim

$80→$20

Buy

16.96%

Upside

Reiterated

09/29/25

Guggenheim cuts MoonLake Immunotherapeutics price target, removes as Best IdeaGuggenheim cuts MoonLake Immunotherapeutics price target, removes as Best Idea

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MoonLake Immunotherapeutics

3 Months

xxx

Success Rate

17/26 ratings generated profit

Average Return

+29.54%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +29.54% per trade.

1 Year

Andreas ArgyridesOppenheimer

Success Rate

9/17 ratings generated profit

Average Return

+16.12%

reiterated a buy rating 2 months ago

Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +16.12% per trade.

2 Years

xxx

Success Rate

10/28 ratings generated profit

Average Return

+13.57%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.71% of your transactions generating a profit, with an average return of +13.57% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MLTX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MLTX has received 16 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. MLTX average Analyst price target in the past 3 months is 24.10.

Each month's total comprises the sum of three months' worth of ratings.

MLTX Financial Forecast

MLTX Earnings Forecast

Next quarter’s earnings estimate for MLTX is -$0.99 with a range of -$1.14 to -$0.73. The previous quarter’s EPS was -$1.10. MLTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MLTX has Performed in-line its overall industry.

No data currently available

MLTX Sales Forecast

Next quarter’s sales forecast for MLTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MLTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MLTX has Performed in-line its overall industry.

MLTX Stock Forecast FAQ

What is MLTX’s average 12-month price target, according to analysts?

Based on analyst ratings, MoonLake Immunotherapeutics’s 12-month average price target is 24.10.

What is MLTX’s upside potential, based on the analysts’ average price target?

MoonLake Immunotherapeutics has 40.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MLTX a Buy, Sell or Hold?

MoonLake Immunotherapeutics has a consensus rating of Moderate Buy which is based on 9 buy ratings, 2 hold ratings and 1 sell ratings.

What is MoonLake Immunotherapeutics’s price target?

The average price target for MoonLake Immunotherapeutics is 24.10. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $5.00. The average price target represents 40.94% Increase from the current price of $17.1.

What do analysts say about MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of MLTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

MLTX Analyst Ratings

MLTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering MoonLake Immunotherapeutics

MLTX Analyst Recommendation Trends

MLTX Financial Forecast

MLTX Earnings Forecast

MLTX Sales Forecast

MLTX Stock Forecast FAQ

Detailed List of Analyst Forecasts